Bayer's Legal Overhang Fades as Q2 Numbers Give Analysts a Fresh Target Range
Published on 08/06/2026 at 02:54 | Redaktion boerse-global.de
The chemistry of Bayer's investment case has shifted in a matter of days. A landmark US Supreme Court ruling and a quarterly earnings beat have combined to pull the stock out of its legal defensive crouch, prompting a wave of target-price hikes from the analyst community. The shares responded by climbing 2.15 percent on Wednesday to trade at 49.44 euros, still roughly 8 percent shy of the 52-week high of 53.86 euros — a gap that looks increasingly closable.
Supreme Court Ruling Reshapes the Litigation Landscape
The pivotal legal development came on Tuesday, when the US Supreme Court ruled in the John Durnell case that state-level warning requirements cannot exceed the labeling standards approved by the Environmental Protection Agency. The decision strips the legal foundation from thousands of glyphosate-related claims against Bayer's Monsanto subsidiary, establishing federal law's supremacy over divergent state rules on cancer warnings. It follows a similar ruling in late June, which held that Bayer cannot be held liable for failing to warn about cancer risks when the EPA does not mandate such warnings in the first place.
The ruling's immediate impact is visible in the Missouri glyphosate class-action settlement process. Monsanto and plaintiffs' attorneys have pushed the final court hearing on the proposed 7.25 billion dollar settlement from August 19 to September 10, according to Dow Jones, citing additional opt-out requests that require review in light of the Supreme Court's decision. Meanwhile, Bayer continues to await a ruling from the Washington Supreme Court in the PCB case Erickson, where a lower court had awarded 185 million dollars in damages against the company.
Crop Science Carries the Quarter
Operationally, the second quarter delivered a mixed but ultimately encouraging picture. Group revenue rose 2.2 percent on a currency-adjusted basis to 10.9 billion euros in Q2, while EBITDA before special items advanced 1.9 percent to 2.1 billion euros. Adjusted earnings per share came in at 0.95 euros — down 16.7 percent year-on-year, yet still ahead of market expectations.
Should investors sell immediately? Or is it worth buying Bayer?
The Crop Science division proved the quarter's backbone, with sales climbing 4 percent to 4.9 billion euros. Glyphosate revenue jumped 13 percent, while soybean products surged 17 percent. The pharma division told a more bifurcated story: growth drivers NUBEQA and KERENDIA expanded 64 percent and 83 percent respectively, but the mature franchises Xarelto and Eylea contracted by 42 percent and 33 percent as patent expirations take their toll. Overall pharma growth limped in at 1 percent, reaching 4.5 billion euros.
For the first half of 2026, Bayer posted currency- and portfolio-adjusted revenue growth of 3 percent to 24.3 billion euros. Core earnings per share climbed at the same pace to 3.66 euros, while EBITDA before special items rose 7 percent to 6.6 billion euros. Free cash flow, however, deteriorated to minus 2.7 billion euros from minus 1.4 billion euros a year earlier, dragged down by litigation-related payments.
Analysts Race to Raise Targets
The response from the sell-side was unusually uniform in its optimism. Goldman Sachs analyst James Quigley lifted his price target from 62.50 to 63.50 euros, maintaining a "Buy" rating. His rationale: strong financial performance, the value embedded in the pharma business, the clarification of glyphosate risks, and a shrinking conglomerate discount. UBS's Matthew Weston followed with an increase from 52 to 62 euros, also at "Buy," arguing that the core operating result beat consensus by 10 percent — a beat achieved without any new glyphosate developments, meaning the operational momentum alone justifies the upgrade.
JPMorgan raised its target from 50 to 61 euros and upgraded to "Overweight," while the DZ Bank lifted its fair value from 54 to 60 euros with a "Kaufen" recommendation, pointing specifically to progress on debt reduction. The lone dissenter is Jefferies, which held its target at 46 euros with a "Hold" rating — the sole bearish outlier in a target range that now spans 46 to 63.50 euros.
Bayer at a turning point? This analysis reveals what investors need to know now.
Debt Reduction Takes Center Stage
Beyond the income statement, the balance sheet is drawing increasing attention. Net financial debt stood at 33.6 billion euros at mid-year, but management expects it to fall to between 29 and 30 billion euros by year-end, thanks to a 3 billion euro capital injection from Apollo — a more aggressive deleveraging path than the previously guided 32 to 33 billion euros. For a company whose leverage has long been flagged as a drag by analysts, that trajectory marks tangible progress, even if the DZ Bank notes that net debt remains elevated by its own assessment.
What Comes Next
CEO Bill Anderson, speaking at the results presentation, reiterated that a breakup into pharma, agriculture, and consumer health divisions remains a strategic option — a possibility that now carries less baggage given the Supreme Court's ruling has eased the legal pressure. The stock has already priced in much of the improvement: it is up 33.48 percent year-to-date and 96.85 percent over twelve months. Whether the valuation gap to peers continues to close will depend on how swiftly the remaining legal matters — the Missouri settlement hearing in September and the pending PCB ruling in Washington — are resolved.
Ad
Bayer Stock: New Analysis - 6 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
